amaxa - Part of the Lonza Group
 
 
You are not logged in. Log in

Mon, September 03 2007 09:00 AM

HudsonAlpha Institute adopts Nucleofector Technology in pursuit of its Research Goals


The HudsonAlpha Institute for Biotechnology recognizes the Nucleofector Technology as an ideal tool for developing reproducible, non-viral based, optimized transfection protocols for the cell lines included in the National Cancer Institute's drug discovery panel.

Download the > press release




> Back to: Public Relations

   

What’s Important to You?

Tell us how you like to do your transfection experiments & enable us to serve you better!